Filtered By:
Nutrition: Vitamins
Countries: Japan Health
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 86 results found since Jan 2013.
Relationship Between Dietary Vitamin D and Deaths From Stroke and Coronary Heart Disease Brief Report
Background and Purpose—There is growing evidence about the importance of vitamin D for cardiovascular health. Therefore, we examined the relationship between dietary vitamin D intake and risk of mortality from stroke and coronary heart disease in Japanese population.Methods—A prospective study encompassing 58 646 healthy Japanese adults (23 099 men and 35 547 women) aged of 40 to 79 years in whom dietary vitamin D intake was determined via a self-administered food frequency questionnaire. The median follow-up period was 19.3 years (1989–2009). The hazard ratios and 95% confidence intervals of mortality were calcu...
Source: Stroke - January 22, 2018 Category: Neurology Authors: Haytham A. Sheerah, Ehab S. Eshak, Renzhe Cui, Hironori Imano, Hiroyasu Iso, Akiko Tamakoshi Tags: Cardiovascular Disease, Diet and Nutrition, Epidemiology, Risk Factors, Cerebrovascular Disease/Stroke Brief Reports Source Type: research
Characteristics of Ischemic Versus Hemorrhagic Stroke in Patients Receiving Oral Anticoagulants: Results of the PASTA Study
Conclusion The presence of CMBs, a history of stroke, natriuretic peptide and D-dimer levels, and PT-INR may be useful for risk stratification of either IS/TIA or ICH development in patients with AF receiving OACs.PMID:34483213 | DOI:10.2169/internalmedicine.8113-21
Source: Internal Medicine - September 6, 2021 Category: Internal Medicine Authors: Satoshi Suda Arata Abe Yasuyuki Iguchi Yoshiki Yagita Takao Kanzawa Seiji Okubo Nobuyuki Ohara Takayuki Mizunari Mineo Yamazaki Nobuhito Nakajima Kimito Kondo Shigeru Fujimoto Takeshi Inoue Takeshi Iwanaga Yuka Terasawa Kensaku Shibazaki Yu Kono Makoto Na Source Type: research
Dietary intake of antioxidant vitamins and risk of stroke: the Japan Public Health Center – based Prospective Study
Dietary intake of antioxidant vitamins and risk of stroke: the Japan Public Health Center–based Prospective Study
European Journal of Clinical Nutrition advance online publication, July 12 2017.
doi:10.1038/ejcn.2017.71
Authors: S Uesugi, J Ishihara, H Iso, N Sawada, R Takachi, M Inoue, S Tsugane & for the JPHC Study Group
Source: European Journal of Clinical Nutrition - July 12, 2017 Category: Nutrition Authors: S Uesugi J Ishihara H Iso N Sawada R Takachi M Inoue S Tsugane Source Type: research
Dietary intake of antioxidant vitamins and risk of stroke: the Japan Public Health Center–based Prospective Study
European Journal of Clinical Nutrition, Published online: 12 July 2017; doi:10.1038/ejcn.2017.71
Source: European Journal of Clinical Nutrition - July 12, 2017 Category: Nutrition Authors: S Uesugi J Ishihara H Iso N Sawada R Takachi M Inoue S Tsugane for the JPHC Study Group Source Type: research
Anti-inflammatory and antiplatelet effects of non-vitamin K antagonist oral anticoagulants in acute phase of ischemic stroke patients
Recently, non-vitamin K antagonist oral anticoagulants such as direct thrombin and direct factor Xa inhibitors have been prescribed for prevention of embolic stroke. While in Japan, argatroban, also a direct t...
Source: Clinical and Translational Medicine - January 12, 2018 Category: Internal Medicine Authors: Taizen Nakase, Junta Moroi and Tatsuya Ishikawa Tags: Research Source Type: research
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Seaweed intake and risk of cardiovascular disease: the Japan Public Health Center-based Prospective (JPHC) Study.
CONCLUSIONS: Seaweed intake was inversely associated with risk of ischemic heart disease.
PMID: 31518387 [PubMed - as supplied by publisher]
Source: The American Journal of Clinical Nutrition - September 12, 2019 Category: Nutrition Authors: Murai U, Yamagishi K, Sata M, Kokubo Y, Saito I, Yatsuya H, Ishihara J, Inoue M, Sawada N, Iso H, Tsugane S, JPHC Study Group Tags: Am J Clin Nutr Source Type: research
Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias
CONCLUSIONS: This meta-analysis showed that the evidence is uncertain to inform the decision to either interrupt or continue anticoagulation therapy around CA procedure in adults with arrhythmia on outcomes of thromboembolic events, major and minor bleeding, all-cause mortality, asymptomatic thromboembolic events, and a composite endpoint of thromboembolic events (stroke, systemic embolism, major bleeding, and all-cause mortality). Most studies in the review adopted a minimal interruption strategy which has the advantage of reducing the risk of bleeding while maintaining a lower level of anticoagulation to prevent periproc...
Source: Cochrane Database of Systematic Reviews - October 21, 2021 Category: General Medicine Authors: Ghada A Bawazeer Hadeel A Alkofide Aya A Alsharafi Nada O Babakr Arwa M Altorkistani Tarek S Kashour Michael Miligkos Khalid M AlFaleh Lubna A Al-Ansary Source Type: research
Association between Acid-Suppressive Drugs and Clinical Outcomes in Patients with Nonvalvular Atrial Fibrillation
ConclusionsASDs were significantly associated with all-cause mortality in patients with NVAF taking OACs.
Source: Drugs in R&D - July 19, 2022 Category: Drugs & Pharmacology Source Type: research
Comparison of short-term clinical outcomes between low-dose prasugrel and clopidogrel as part of triple antithrombotic therapy in patients requiring oral anticoagulant therapy and percutaneous coronary intervention
ConclusionsCombination of low-dose prasugrel and DOAC was associated with lower incidence of MI, ischemic stroke, and blood transfusion. Low-dose prasugrel may be feasible as part of triple therapy in patients undergoing PCI.
Source: PLoS One - July 28, 2022 Category: Biomedical Science Authors: Hideki Kitahara Source Type: research
Risk Profile and 1-Year Outcome of Newly Diagnosed Atrial Fibrillation in Japan - Insights From GARFIELD-AF.
CONCLUSIONS: GARFIELD-AF continues to provide important information on the homogeneity and heterogeneity of baseline characteristics and treatment patterns in patients with newly diagnosed NVAF. This diversity reflects the differences in outcomes in Japan compared with the rest of the world.
PMID: 30518731 [PubMed - as supplied by publisher]
Source: Circulation Journal - December 4, 2018 Category: Cardiology Authors: Koretsune Y, Etoh T, Katsuda Y, Suetsugu T, Kumeda K, Sakuma I, Eshima K, Shibuya M, Ando SI, Yokota N, Goto S, Pieper KS, Allu J, Kakkar AK, GARFIELD-AF Investigators Tags: Circ J Source Type: research
